Governance Guidance for Biopharma Board Members
Experience-based counsel for the people who sit in the boardroom and make the decisions. Not theory. Not checklists. The real work of governing clinical-stage companies.
Read the LatestWhat We Cover
Governance Fundamentals
The foundational knowledge that generic governance resources don't teach
Browse →Clinical-Stage Decision Making
The board's role in the decisions that define clinical-stage companies
Browse →Capital & Strategic Transactions
Financial governance, fundraising oversight, and exit preparation
Browse →Board Dynamics & Effectiveness
The human and organizational dimensions of board governance
Browse →Recent Articles
The Board Chair and Lead Independent Director in a Clinical-Stage Biopharma
Who runs the board is the most underexamined governance question in a clinical-stage biopharma. The standard answers borrowed from large-cap governance do not fit a five-seat board. What the chair role actually requires, why the default arrangement usually fails, and how the structure should evolve as the company matures.
Board Committees in a Five-Seat Biopharma
The standard four-committee architecture borrowed from large-cap boards does not fit a clinical-stage company with three independent directors. What committees actually need to exist, what work belongs to the full board, and the design choices that matter before an IPO or transaction.
Governance During Crisis: Data Fraud, Safety Signals, and Scandal
The board's playbook when things go catastrophically wrong — the first 48 hours, the communication architecture, and the work of recovery. With reference cases from torcetrapib, Cassava Sciences, and Insys Therapeutics.
Stay Informed
A weekly newsletter with governance insights, case studies, and analysis for biopharma board members.
No spam. Unsubscribe anytime.